文献速递腹部介入CTMRDSA

PPRD评分可对接受索拉非尼联合经动脉化疗栓塞治疗的肝细胞癌合并门静脉癌栓患者进行分层

The PPRD score stratifies patients with hepatocellular carcinoma and portal vein tumor thrombus treated with sorafenib plus transarterial chemoembolization.
PubMed 文献 · Eur Radiol · 2020-07-29

本研究纳入184例肝细胞癌合并门静脉癌栓并接受索拉非尼联合经动脉化疗栓塞治疗的患者,通过多因素分析确定与总生存期独立相关的因素,建立PPRD评分(0–11分)并在72例外部队列中验证。评分将患者分为 favorable(0分)、intermediate(1–4分)和dismal(>4分)三组,中位生存期分别为34.0、20.0和7.0个月(p < 0.001),且疾病进展时间(TTP)也按相同预后组分层(p < 0.001),外部队列验证了该评分的预后价值。

要点

  • PPRD评分由体力状态、门静脉癌栓范围、初始影像学反应和索拉非尼相关皮肤毒性构成。
  • 评分0分为预后良好组,1–4分为中间组,>4分为预后不良组。
  • 三组中位生存期分别为34.0个月、20.0个月和7.0个月(p < 0.001)。

关键影像表现/征象

  • 多因素分析显示体力状态、门静脉癌栓范围、初始影像学反应和索拉非尼相关皮肤毒性是与总生存期独立相关的预测因素。

诊断标准与关键数值

  • PPRD评分范围为0至11分,由体力状态、门静脉癌栓范围、初始影像学反应和索拉非尼相关皮肤毒性构成。
  • 评分0分为预后良好组,1–4分为中间组,>4分为预后不良组。
  • 三组中位生存期分别为34.0个月、20.0个月和7.0个月(p < 0.001)。
  • 疾病进展时间(TTP)也按相同预后组分层(p < 0.001)。

临床应用与阅片要点

  • 该评分可用于对接受索拉非尼联合TACE治疗的肝细胞癌合并门静脉癌栓患者进行预后分层,帮助识别可能从治疗中获益的群体。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To identify clinical prognostic and predictive factors in patients with hepatocellular carcinoma (HCC) and portal vein tumor thrombus (PVTT) undergoing sorafenib plus transarterial chemoembolization (TACE) and establish a prognostic score for these patients.

METHODS: Between January 2012 and December 2017, 184 consecutive patients with HCC and PVTT were concurrently treated with sorafenib and TACE. Univariate and multivariate analyses were performed to explore the clinical factors independently correlated with overall survival (OS). A prognostic score was then developed to identify different prognoses in an initial cohort and validated in an external cohort (n = 72).

RESULTS: In the multivariate analysis, performance status, extension of PVTT, initial radiological response, and sorafenib-related dermatologic toxicity were identified as predictors associated with OS. These factors were used to develop a prognostic score (PPRD score, range from 0 to 11). The median survival was found to decrease as the PPRD score increased, and patients were stratified into a favorable group (0 points), intermediate group (1-4 points), and dismal group (> 4 points). The median survival of patients in the three groups was 34.0 months, 20.0 months, and 7.0 months, respectively (p < 0.001). Additionally, the time to progression (TTP) (p < 0.001) was stratified along the same prognostic groups. The external validation cohort confirmed the prognostic scores.

CONCLUSIONS: The proposed score system can accurately stratify the outcomes of patients with HCC and PVTT treated with sorafenib plus TACE to help identify which group of patients may benefit from treatment.

KEY POINTS: • The survival benefits of patients with advanced HCC treated with sorafenib plus TACE remains controversial. • The independent factors associated with survival were identified to develop a prognostic score, called the PPRD score (standing for performance status, PVTT grade, radiological response, and sorafenib-related dermatologic toxicity); the median survival decreases as the score increases. • The scoring system can accurately stratify the survival benefits of patients with HCC and PVTT treated with combination therapy and help to identify which group of patients may benefit from the treatment. Graphical abstract.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Miao H, Xie W, et al. The PPRD score stratifies patients with hepatocellular carcinoma and portal vein tumor thrombus treated with sorafenib plus transarterial chemoembolization. Eur Radiol. 2020. PMID: 32728770. doi:10.1007/s00330-020-07078-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。